A fundamental understanding of scientific processes underlie many of the great discoveries of modern medicine that have transformed the healthcare of patients. As a clinician-scientist dedicated to the study of Alzheimer’s disease, my hope is to take discoveries in our laboratory all the way to the clinic so that we can alleviate the burden that this devastating condition places on the individual, their families and loved ones, and our society.
Dr. Jack Jhamandas is currently Distinguished University Professor in the Division of Neurology, Department of Medicine at the University of Alberta. He received his BSc in applied physics and MSc in biophysics from the University of Alberta and his MD from the University of Calgary. He completed his clinical training in internal medicine at the Toronto Western Hospital and in neurology at the Montreal Neurological Institute. He received his PhD in neuroscience from McGill University.
Leadership and Collaborations:
Dr. Jhamandas is currently chair of the Steering Committee of Campus Alberta Neuroscience, a province-wide tri-university organization dedicated to increasing the impact of neuroscience and mental health research, education and translation. He has previously served as vice-president, research, for the Association of Faculties of Medicine of Canada. He has served on national scientific granting panels, on the board of directors of the Heart and Stroke Foundation of Alberta, N.W.T. & Nunavut, as a member of the inaugural advisory board for the Canadian Institutes of Health (CIHR) Research Institute of Neuroscience, Mental Health and Addiction. He has also served as Associate Dean Research for the Faculty of Medicine & Dentistry at the University of Alberta, Vice-President Research for the Association of Faculties of Medicine of Canada (AFMC) and Chair of the Steering Committee of Campus Alberta Neuroscience.
Awards and Accolades:
In recognition of his scholastic achievements, Dr. Jhamandas was awarded the Gold Medal in Medicine from the Royal College of Physicians and Surgeons of Canada; a Killam Professorship; Capital Health researcher of the year award; the Department of Medicine Research Achievement Award. He has held a Tier 1 Canada Research Chair in Alzheimer's Research and has been elected as a Fellow of the Canadian Academy of Health Sciences and the American Neurological Association.
In 2018, he co-authored The AFMC's evolution as a successful advocate for health research: where to next? with Dr. Tom Marrie: https://afmc.ca/sites/default/files/flipping_book/75years/mobile/index.html?1.1
Dr. Jhamandas provides instruction, training and mentorship at all levels of medical education—from classroom instruction in neuroscience to teaching and mentoring in clinical skills to medical students and residents in neurology and other clinical disciplines. He organized and conducted basic neuroscience teaching sessions on an annual basis for neurology residents for many years and has served on the Neurology Board of Examiners for the Royal College of Physicians and Surgeons of Canada. His teaching contributions have been recognized through awards of Teacher of the Year (2014) for neurology and Discovery Learning Preceptor Excellence Award (2013-2014).
Dr. Jhamandas’ research program focuses on studying misfolded proteins such as amyloid beta protein and neurodegenerative processes underlying Alzheimer's disease (AD). His current work is aimed at developing and testing novel disease modifying therapies for AD based upon the amylin receptor. His research has been funded by Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Alberta Innovates—Health Solutions, Alberta Prion Research Institute, Alzheimer Society of Alberta & Northwest Territories, the University Hospital Foundation and other national and provincial granting agencies.
He is a grant reviewer for national and international funding agencies including Medical Research Council of Canada, Heart and Stroke Foundation of Canada, Canadian Diabetic Association, Alberta Heart and Stroke Foundation, Wellcome Trust (United Kingdom), National Science Association (USA), BC Healthcare Research Foundation. He has served as an ad hoc reviewer for many journals including Nature Communications, Proceedings of the National Academy of Sciences (USA), Journal of Biological Chemistry, Journal of Neuroscience and many others in the discipline of neuroscience.
Alzheimer’s disease, Amylin peptides, Amyloid, Animal models of Alzheimer’s disease, Drug Discovery, Memory and Learning, Neurodegeneration
Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D. Actions of β-amyloid protein on human neurons are expressed through the amylin receptor. American Journal of Pathology 178: 140 – 149, 2011.
Fu W, Ruangkittisakul A, MacTavish D, Shi J, Ballanyi K, and Jhamandas, JH. Amyloid beta (Aβ) peptide directly activates Amylin-3 receptor subtype by triggering multiple intracellular signalling pathways. The Journal of Biological Chemistry 287: 18820-18830, 2012.
Kimura R, MacTavish D, Yang J, Westaway D, and Jhamandas JH. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. Journal of Neuroscience 32: 17401 – 17406, 2012
Fu W, Shi D, Westaway D, and Jhamandas JH. Bioenergetic mechanisms in astrocytes may contribute to amyloid plaque deposition and toxicity. The Journal of Biological Chemistry 2015 Mar 26. pii: jbc.M114.618157. [Epub ahead of print], 2015.
Kimura R, MacTavish D, Yang J, Westaway D, Jhamandas JH. Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation. Mol Neurobiol. 4:748-754. doi: 10.1007/s12035-016-9684-x. Epub 2016 Jan 15, 2017.
Soudy R, Patel A, Fu W, Kaur K, MacTavish D, Westaway D, Davey R, Zajac J, Jhamandas J. Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer’s. Alzheimer’s and Dementia: Translational Research and Clinical Interventions. 3: 44-56, 2017
Fu W, Patel A, Kimura R, Soudy R, Jhamandas JH. Amylin Receptor: A Potential Therapeutic Target for Alzheimer's Disease. Trends in Molecular Medicine. 23(8): 709-720, 2017.
Fu W, Vukojevic V, Patel A , Soudy R, MacTavish D, Westaway D, Kaur K, Goncharuk V, Jhamandas J. Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation. Journal of Neuroinflammation. 14(1): 199, 2017.
Soudy R, Kimura R, Patel A, Fu W, Kaur K, Westaway D, Yang J , Jhamandas J. Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model. Scientific Reports. 9:10942 https://doi.org/10.1038/s41598-019-47255-9, 2019
2016 - 2018 AB-Innovates–Bio Solutions (Alzheimer Society of Alberta and NWT/Alberta Prion Research Institute). Novel therapeutics for Alzheimer’s disease: Amylin receptor based compounds.
2018-2020 AB-Innovates – Alberta Alzheimer Research Program VI. Genetic depletion of amylin receptors improves memory and learning in transgenic Alzheimer’s disease mice.
2018-2021 Canadian Institutes of Health Research – The amylin receptor: a potential therapeutic target for Alzheimer’s disease.
Dr. Jhamandas provides out-patient care in neurology, specifically neuromuscular diagnostics, at the Kaye Edmonton Clinic and the University of Alberta Hospital.
Doctor of Philosophy
- McGill University
Fellow Royal College Physicians Can
- McGill University
- University of Calgary
Master of Science
- University of Alberta
Bachelor of Science
- University of Alberta